Clinical trials: IPMN, Pancreatic
IPMN, IPMN, Pancreatic
Impact of GLP-1 Receptor Agonists on Patients With IPMN
This study investigates the impact of GLP-1 receptor agonists (GLP-1 RAs) on patients with intraductal papillary mucinous neoplasms (IPMNs), a type of pancreatic cystic neoplasm that can progress to malignancy.
- Conditions
- IPMN, IPMN, Pancreatic, GLP-1, Intraductal Papillary Mucinous Neoplasm of Pancreas
- Trial name
- IPMN-GLP1RA (NCT07014709)
- Testing
- GLP1 receptor agonist
- Where
- Switzerland
- Volunteers
- 30 people
- Sponsor
- Hôpital Fribourgeois
Pancreas Head Cancer, Pancreas Adenocarcinoma
Preventing Postoperative Complications in Patients Undergoing High-risk Pancreatoduodenectomy With a Bundle Approach Including Hydrocortisone, Octreotide, and the Teres Ligament Patch (PANENCA)
The PANENCA trial aims to reduce postoperative complications in patients undergoing pancreatoduodenectomy (also known as a Whipple procedure), a complex surgical operation performed to remove tumors located in or near the head of…
- Conditions
- Pancreas Head Cancer, Pancreas Adenocarcinoma, IPMN, Pancreatic, Cholangio Carcinoma
- Trial name
- PANENCA (NCT07262957)
- Testing
- HOP bundle
- Where
- Netherlands
- Volunteers
- 400 people
- Sponsor
- Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
PAPILLARY AND MUCINOUS INTRACANAL TUMORS OF THE PANCREAS
Early Detection of Pancreatic Cancer in Patients With Papillary and Mucinous Intracanal Tumours of the Pancreas Papillary and Mucinous Tumours of the Pancreas
This trial is a prospective, exploratory and descriptive study. The primary objective is to identify early diagnostic biomarkers in patients with TIPMP based on the analysis of Treg lymphocyte subpopulations and epigenetic…
- Trial name
- NCT06000553
- Testing
- blood sampling at inclusion, 6 months, 1 year and 2 years. Tumor and intracystic fluid samples are taken only if a biopsy is planned following MRI results.
- Volunteers
- 360 people
- Sponsor
- Institut Paoli-Calmettes
IPMN, Pancreatic Cancer
Surveillance Discontinuation in 5 Year Stable Trivial Branch Duct Intraductal Papillary Mucinous Neoplasms
BACKGROUND: Patients with trivial branch duct intraductal papillary mucinous neoplasm (BD IPMN) which remain s stable over 5 years reportedly do not have an increased risk of developing pancreatic cancer (PC) compared to the…
- Trial name
- TRIVIAL (NCT07056972)
- Testing
- Discontinuation of surveillance
- Volunteers
- 394 people, healthy volunteers welcome
- Sponsor
- Azienda Ospedaliera di Padova
Intraductal Papillary Mucinous Neoplasm of Pancreas
Feasibility Trial of EUS-PCA in IPMN Pancreatic Cysts
The goal of this single-arm intervention trial is to determine the feasibility of implementing endoscopic ultrasound-guided pancreatic cyst chemoablation (EUS-PCA) using gemcitabine and paclitaxel for intraductal papillary…
- Trial name
- NCT06162468
- Testing
- Endoscopic ultrasound-guided pancreatic cyst chemoablation (EUS-PCA) using gemcitabine and paclitaxel
- Where
- 2 sites in New Zealand
- Volunteers
- 20 people
- Sponsor
- University of Auckland, New Zealand
IPMN, Pancreatic
Integration of Multiomics Markers for Invasive IPMNs Identification Through the Set-up of the INvasive Cyst bIomarkers Detection (INCITE) Consortium
Although intraductal papillary mucinous neoplasms (IPMNs) represent potential precursors of pancreatic cancer, IPMNs with invasive cancer are rare.
- Trial name
- INCITE (NCT06694792)
- Where
- Italy
- Volunteers
- 800 people
- Sponsor
- IRCCS San Raffaele
Pancreatic Cyst
Confocal Laser Endomicroscopy as an Imaging Biomarker for the Diagnosis of Pancreatic Cystic Lesions
The study schema is shown in Figure 4. (A) All patients referred to one of the participating academic centers for EUS evaluation of the PCL will be enrolled in the protocol if they satisfy inclusion criteria.
- Trial name
- CLIMB (NCT03492151)
- Where
- 10 sites in United States
- Volunteers
- 500 people
- Sponsor
- Ohio State University Comprehensive Cancer Center
Pancreatic Ductal Adenocarcinoma (PDAC), Colorectal Cancer (CRC)
Advanced Therapies for Liver Metastases
Liver metastases (MTS) are the main cause of death for patients affected by colorectal carcinoma (CRC) and pancreatic ductal adenocarcinoma (PDAC), thus representing the major unmet clinical need for these malignancies.
- Conditions
- Pancreatic Ductal Adenocarcinoma (PDAC), Colorectal Cancer (CRC), Liver Metastasis, IPMN, Pancreatic
- Trial name
- LiMeT (NCT04622423)
- Where
- Italy
- Volunteers
- 625 people, healthy volunteers welcome
- Sponsor
- IRCCS San Raffaele
Neoplasm of Pancreas, IPMN, Pancreatic
Study of IPMN Progression Prevention With Tocotrienol (SIPP-T3)
This is a randomized, double-blind, placebo-controlled trial, investigating whether treatment with δ-tocotrienol (a.k.a. Delta-tocotrienol, abbreviated as DT3) will prevent the progression of Intraductal Papillary Mucinous…
- Trial name
- NCT06519097
- Testing
- Vitamin E Delta Tocotrienol
- Where
- 2 sites in United States
- Volunteers
- 4 people
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
IPMN, Pancreatic, IPMN
Intraductal Papillary Mucinous Neoplasm (IPMN) Database - A Tool to Predict Pancreatic Cancer
Pancreatic cancer is the 5th leading cause of cancer death in Australia. Surgery remains the most effective treatment for early pancreatic cancer and currently the only potential for cure.
- Trial name
- MAPS (NCT05117723)
- Where
- Australia
- Volunteers
- 1,000 people
- Sponsor
- St Vincent's Hospital Melbourne
IPMN, Pancreatic
A Long-term Follow-up Cohort Study in Patients With Intraductal Papillary Mucinous Neoplasm
Study objective: To establish a long-term follow-up cohort of patients with IPMN, study the follow-up, clinical outcomes and prognostic factors of patients with IPMN, and provide a basis for clinical decisions and guidelines.
- Trial name
- NCT05593393
- Testing
- Endoscopic ultrasound
- Volunteers
- 1,500 people
- Sponsor
- Peking Union Medical College Hospital
Pancreatic Cyst, IPMN
Utility of EUS-guided Microbiopsies in Pancreatic Cystic Lesions
The purpose of this study is to determine clinical impact of EUS-guided microbiopsy procedure and supplementary molecular analyses compared to standard diagnostic workup of pancreatic cysts.
- Conditions
- Pancreatic Cyst, IPMN, Mucinous Cyst, Pancreatic Adenocarcinoma
- Trial name
- NCT03578445
- Testing
- EUS-guided microbiopsy, Next Generation Sequencing
- Where
- Denmark
- Volunteers
- 101 people
- Sponsor
- Herlev Hospital
Pancreas Neoplasms
Use of Celecoxib in Patients With Intraductal Papillary Mucinous Neoplasms (IPMNs)
The purpose of the study is to find out whether the drug celecoxib has beneficial effects on people with pre-cancerous lesions of the pancreas.
- Trial name
- NCT00198081
- Testing
- COX-2 Inhibitor 6-8 weeks prior to surgery, COX-2 Inhibitor for 6 months prior to follow-up EUS or ERCP
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- Indiana University
Pancreatic Cancer, Neoplasm
Family and Personal History of Malignancy in Intraductal Papillary Mucinous Neoplasm (IPMN)
This is a retrospective observational study to determine the proportion of patients with a family history of pancreatic cancer and other malignancies among patients who have intraductal papillary mucinous neoplasm (IPMN).
- Trial name
- NCT01104077
- Where
- United States
- Volunteers
- 277 people
- Sponsor
- Columbia University
Pancreatic Cancer, Chronic Pancreatitis
Diagnostic Utility of Protein Biomarkers in Pancreatic Ductal Adenocarcinoma
The goal of this prospective multicenter observational study is to evaluate the diagnostic accuracy of blood-based protein biomarkers for detecting pancreatic ductal adenocarcinoma (PDAC) in adults aged 18 years and older.
- Conditions
- Pancreatic Cancer, Chronic Pancreatitis, Intraductal Papillary Mucinous Neoplasm, Mucinous Cystic Neoplasm
- Trial name
- NCT07875582
- Testing
- Blood-Based Protein Biomarker Assessment
- Where
- Romania
- Volunteers
- 100 people
- Sponsor
- Grigore T. Popa University of Medicine and Pharmacy
Neoplasm, Pancreatic Cancer
Use of PET Imaging to Distinguish Malignant From Benign IPMN
Intraductal papillary mucinous neoplasm (IPMN) is a cystic pancreatic lesion that is a precursor to invasive pancreatic cancer. Differentiating whether an IPMN lesion is benign or malignant is critical, as the prognosis and…
- Trial name
- NCT01104116
- Testing
- [18F]-FDG PET/CT imaging
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- Columbia University
IPMN, Pancreatic, Pancreatic Cancer, Resected
Venous Resection in Patients Undergoing Pancreatic Surgery
Pancreatic surgery is the only treatment in the multimodality approach to pancreatic cancer sine qua non long-term survival cannot be achieved.
- Conditions
- IPMN, Pancreatic, Pancreatic Cancer, Resected, Pancreatic Cancer Borderline, Chronic Pancreatitis
- Trial name
- VENUS (NCT07621029)
- Where
- 2 sites in Netherlands, Sweden
- Volunteers
- 1,000 people
- Sponsor
- Sahlgrenska University Hospital
Intraductal Papillary Mucinous Neoplasm of Pancreas
Aspiration of Duodenopancreatic Juice After Secretin Stimulation vs Endoscopic Aspiration for Molecular Analysis of Intraductal Papillary Mucinous Intraductal Neoplasia.
Study to evaluate aspiration of duodenopancreatic juice after secretin stimulation (ADPJ-secr)versus endoscopic ultrasound-guided fine needle aspiration (EUS-FNA) for molecular analysis of intraductal papillary mucinous…
- Trial name
- RESCUE (NCT05914077)
- Testing
- Secretin, Endoscopic aspiration, Endoscopic ultrasound-guided fine needle aspiration
- Where
- Spain
- Volunteers
- 140 people
- Sponsor
- Fundacion Clinic per a la Recerca Biomédica
Intraductal Papillary Mucinous Neoplasms, Pancreatic Exocrine Insufficiency
IPEX Study: Pancreatic Exocrine Insufficiency as a Functional Marker of Disease Progression in Patients With IPMN
Intraductal Papillary Mucinous Neoplasms (IPMN) are pancreatic cystic neoplasms managed through imaging-based surveillance focused on oncologic risk.
- Trial name
- IPEX (NCT07535125)
- Volunteers
- 600 people
- Sponsor
- A.O.U. Città della Salute e della Scienza
Chronic Pancreatitis, Inflammatory Bowel Diseases
Genomic Resources for Enhancing Available Therapies (GREAT1.0) Study
This is a prospective, descriptive, observational research study designed to observe and document the clinical practice by domain experts, and how the knowledge of new findings that are published in the medical literature affect…
- Conditions
- Chronic Pancreatitis, Inflammatory Bowel Diseases, Hepatitis, NASH - Nonalcoholic Steatohepatitis
- Trial name
- GREAT1 (NCT04306939)
- Testing
- venipuncture, Questionnaires, Additional Sample Collections
- Where
- United States
- Volunteers
- 120,000 people, healthy volunteers welcome
- Sponsor
- University of Pittsburgh